Rapid proteomic analysis for solid tumors reveals LSD1 as a drug target in an end-stage cancer patient


  • S. Doll
  • M.C. Kriegmair
  • A. Santos
  • M. Wierer
  • F. Coscia
  • H.M. Neil
  • S. Porubsky
  • P.E. Geyer
  • A. Mund
  • P. Nuhn
  • M. Mann


  • Molecular Oncology


  • Mol Oncol 12 (8): 1296-1307


  • Recent advances in mass spectrometry (MS)-based technologies are now set to transform translational cancer proteomics from an idea to a practice. Here, we present a robust proteomic workflow for the analysis of clinically relevant human cancer tissues that allows quantitation of thousands of tumor proteins in several hours of measuring time and a total turnaround of a few days. We applied it to a chemorefractory metastatic case of the extremely rare urachal carcinoma. Quantitative comparison of lung metastases and surrounding tissue revealed several significantly upregulated proteins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A). LSD1 is an epigenetic regulator and the target of active development efforts in oncology. Thus, clinical cancer proteomics can rapidly and efficiently identify actionable therapeutic options. While currently described for a single case study, we envision that it can be applied broadly to other patients in a similar condition.